CONFIDENTIAL · INVITATION ONLY
Signal
A Measured Exosome Protocol for Biological Aging
Administered exclusively through Trufa Med, Surfside, Florida.
Initial Cohort: 22 Participants
Aging reflects a degradation of biological signal.
A breakdown in cellular communication driving inflammation,
senescence, and mitochondrial decline.
SIGNAL EXOSOME THERAPY
Preclinical evidence. Early human experience.
Exosomes are extracellular vesicles that carry signaling molecules between cells. Signal delivers GMP manufactured exosomes targeting the communication pathways most associated with biological aging.
Mechanism
Anti-Inflammatory Signaling
Preclinical models indicate modulation of pro-inflammatory cytokine activity and support of immune homeostasis.
Mechanism
Senescence Pathway Modulation
Early evidence suggests reduction in SASP signaling in aged tissue models.
Mechanism
Neuroplasticity Support
Preclinical findings show enhanced markers associated with hippocampal function and synaptic activity.
Preclinical Evidence
Data reflects animal models. Human outcomes may vary.
15–20%
LIFESPAN EXTENSION
Observed in aged murine models
40–60%
SENESCENCE-ASSOCIATED SIGNALING REDUCTION
Preclinical tissue models
Positive
NEUROPLASTICITY MARKERS
Enhanced in preclinical cognitive studies
Biological Safety Profile
Preclinical Toxicology
No toxicity signals in animal studies. Strong biocompatibility across tissue types.
Early Human Experience
No serious adverse events reported globally. Rare cases show only minimal local reactions.
Immunogenicity
No immune rejection or sensitization observed. Exosomes are naturally tolerated by the body.
Longitudinal Observation
Ongoing follow-up in early cohorts shows no delayed adverse effects to date.
Your Protocol: Phase 1 Clinical Structure
4 Infusions. 4 Weeks. Physician Supervised.
Four weekly infusions. Comprehensive biomarker assessment at baseline and week 6. All sessions conducted under direct physician supervision at Trufa Med, Surfside, Florida. Initial cohort: 22 participants.
1
Week 1 — Baseline Assessment & Infusion 1
Biomarker panel. Safety screening. First infusion.
2
Week 2 — Infusion 2
Second infusion. Interim monitoring.
3
Week 3 — Infusion 3
Third infusion. Ongoing tracking.
4
Week 4 — Infusion 4 & Interim Review
Final infusion. Preliminary data review.
5
Week 6 — Post-Intervention Assessment
Full biomarker re-measurement. Private clinical report issued.
Signal Measurement System
INFLAMMATORY MARKERS
CRP, IL-6, TNF-α
SENESCENCE MARKERS
p16, p21, SASP Panel
METABOLIC & MITOCHONDRIAL FUNCTION
NAD+ levels, mitochondrial efficiency, metabolic markers
COGNITIVE & NEUROLOGICAL
BDNF, cognitive assessment, sleep quality
SYSTEMIC AGING MARKERS
Telomere length, epigenetic age, physical performance
Regulatory Framework
Florida Senate Bill 1768
Signal operates within the framework established by Florida SB 1768 — permitting GMP-manufactured regenerative therapies under physician supervision. This is an early-access clinical program, not an FDA-approved treatment.
1
Legal Pathway
Florida SB 1768. GMP exosome therapy under licensed physician supervision.
2
GMP Manufacturing
Pharmaceutical-grade production. Consistent potency, purity, and safety standards.
3
Physician Administration
Every infusion administered by a licensed clinician. Real-time safety monitoring.
4
Structured Oversight
Defined protocol. Documented biomarker tracking. Clinical review at each stage.
Signal is a structured clinical program designed to evaluate individual biological response — with full transparency at every stage.
What to Expect
Structured. Unobtrusive. Precisely managed.
01
Initial Consultation
Private clinical review. Medical history, eligibility, and baseline biomarker panel. ~90 minutes.
02
Weekly Infusions
Four visits, 60–90 minutes each. IV infusion under physician supervision. No downtime.
03
Ongoing Monitoring
Check-ins between sessions. Direct clinical team access throughout.
04
Post-Intervention Assessment
Full biomarker re-measurement at week 6. Results in a private clinical report.
05
Longitudinal Follow-Up
Optional monitoring at 3 and 6 months. Full participant privacy maintained.
Time Commitment
5–6 weeks. 5 visits. No hospitalization.
Clinical Team
Licensed physician oversight at every stage.
Your Data
Private clinical report. Yours to keep. Fully confidential.
Example Biological Response Profile
Early Observations + Modeled Outcomes — individual results will vary.
Illustrative only. Based on preclinical data and early human experience. Initial internal observations are directionally consistent with these patterns. Signal does not guarantee specific outcomes.
Initial internal observations are directionally consistent with these patterns.
35%
CRP (Inflammatory Marker)
Baseline elevated, post-intervention reduced. Illustrative reduction: ~30–40%
28%
p16 (Senescence Marker)
Baseline elevated, post-intervention reduced. Illustrative reduction: ~20–35%
32%
BDNF (Neuroplasticity Marker)
Baseline low-normal, post-intervention improved. Illustrative improvement: ~25–40%
25%
NAD+ (Mitochondrial Function)
Baseline low, post-intervention improved. Illustrative improvement: ~20–30%
Epigenetic Age Score
Baseline elevated vs chronological age, post-intervention closer alignment. Illustrative shift: ~1–3 years
What This Means
Improvements in these markers suggest a positive biological response — not a cure, but a measurable shift.
Variability
Every biology is different. Signal's measurement system captures your individual response precisely.
Your Report
Week 6: a private clinical report with your actual before-and-after data, interpreted by your physician.
Signal
A private clinical program for a very small number of individuals.
Signal is a structured, physician-supervised protocol — available exclusively through Trufa Med, Surfside, Florida.
Administered Exclusively Through
Trufa Med
Concierge Medicine · Surfside, Florida
What You're Entering
Early-Access Protocol
Initial cohort: 22 participants. Intentionally limited for close oversight and protocol refinement.
Israeli-Developed Science
Preclinical evidence across inflammation, senescence, and neuroplasticity.
Comprehensive Measurement
20+ aging biomarkers. Baseline and post-intervention.
GMP-Manufactured
Pharmaceutical-grade. Florida SB 1768 compliant.
Full Clinical Support
Physician oversight, monitoring, and a private data report at completion.
What Happens After the First Cohort
Data Review
Aggregated, anonymized data reviewed by the clinical team.
Protocol Refinement
Findings may inform dosing or structure adjustments. Future iterations may differ.
Future Access
First cohort participants receive priority consideration for subsequent iterations.
Participation is by invitation following clinical review. Further discussion is available privately through Trufa Med.
All participation is confidential. Data is yours. This document is for invited individuals only.